搜索
,,,,,(,150050):,602,,,8,Y-Bocs(CGI)8Y-Bocs7118%,5218%,2(P0105),,:;;:320154:R74914:A:1004-5775(2003)08-0568-03:(1970-),,,,:(2002-029)Double-blindControlResearchofTreatingtheObsessive-compulsiveDisorderbyCombinedMedicineLIUWei,WUZheng,HANHai-ying,etal.(DepartmentofPsychiatry,FirstAffiliatedHospitalofHarbinMedicalUniversity,Harbin150050,China)Abstract:ObjectiveTofindoutthewayoftreatingobsessive-compulsivedisorder(OCD)bycombinedmedicine.Methods60patientwhoobtainedthediagnosticcriteriaweredividedintotreatmentgroupandcontrolgroup.Thetreat2mentgroupwasgivenchlorimipramine,sertralineandphenytoinsodiumtogetheratthesametimeandpatientsofthecon2trolgrouponlyusedthechlorimipramine.Twogroupshadbeentreatedfor8weeksandtheeffectsoftherapywereob2servedbyusingY-Bocsandtreatmenteffectscale.ResultsAtthe8thweek,theY-Bocssubtractivescorerateofthecombinedmedicinegroupwas71.8%andthatofthechlorimipraminegroupwas52.8%.Thedifferencebetweentwogroupswassignificant(P0.05)andtherewasnosignificantdifferenceinthesideeffectsbetweentwogroups.Con2clusionTheremightbeaprominenteffectintreatingtheOCDbycombinedmedicinewhichwouldbegoodtocurethiskindofdisease.Keywords:Combinedmedicine;Obsessive-compulsivedisorder(OCD),,2(NCS),4,,20%30%,11/3,,2,,3,45,6,3(),111120012002,:CCMD-8652720038HEILONGJIANGMEDICALJOURNALVol.27,No.8Aug.2003;1560;;,;,260,21,30,16(5313%),14(4617%)32171318,3126112,30,15(5010%),15(5010%)34111216,3135192(P0105)11211211:3,,11212:Y-Bocs(CGI),4848CGICGI4:(1):,Y-Bocs75%;(2):,,,Y-Bocs50%;(3):,,Y-Bocs25%;(4):Y-Bocs25%,2211248Y-Bocs112Y-Bocs()4823157181712816616241712311818191591311145510742Y-Bocst(P0105t=1131)8,Y-Bocs7118%,5014%,2t(P0105t=3149),2(u=2108P0105),2128,16,10,2,28108422(2=0174P0105),5313%,2617%2t(u=2108P0105)21375250mg,128mg7215mg,50100mg,012014/d:200300mg,226mg6817mg,2(P0105t=5144)214,20,6617%,1,22,7313%22(u=015P0105)TESS82,P0105,3,OCD,5-HT,,1/22/3,4,:(1),,,,,;(2),;(3),,;(4),,,,SSRI,,,5-HT;(5),,Bonnycastle5-HT,,,,3,,,OCD,9652720038HEILONGJIANGMEDICALJOURNALVol.27,No.8Aug.20031,1,1,2(11,518000;21,530000):(Isoflavone)CE(CHD)2(T2DM)85CHDT2DM,(B)(C)(D)(E)CE,(A),OGTT,1246hOGTT,ABCICAM-1E-selectin,DE,2ICAM-1E-selectin150mg500mgC400IUE,CHDT2DM(AS):;;;2;;:32012410:R54114;R58711:A:1004-5775(2003)08-0570-05EffectofAntioxidantonExpressionofAdhesionMoleculeinCHDandTypeIIDiabetesMellitusSUNChuan-bin,ZHANGFan,ZHUCui-feng,etal.(DepartmentofHeartdiseaseCenter,ShenzhenHospitalofBeijingUniversityShenzhenGuangdong,Shenzhen518036,China)Abstract:ObjectiveToinvestigatetheeffectofdifferentdosagesofantioxidant(Isoflavone,VitaminCandE)ontheexpressionofadhesionmoleculesinCHDandTypeIIdiabetesmellitus(T2DM)patients.Methods40diagnosedCHD:(1948-),,,,,,,,,,,OCD:1,1J1,2000,10(6):332334.21M1:,199918:66913,,1J1,1999,25(1):565714,,1J1,1994,20(1):313315PiccinelliM,PiniS,BellantuonoC,etal.TheBritishJournalofpsychiatryTheJournalofMentalSci2enceEfficacyofdrugtreatmentinobsessive-compulsivedisorderAmeta-analyticreviewJ.Br-J-Pschiartry,1995,166(4):42443.6Mataix-Cols-D.Useoffactor-analyzedsymptomdimensionstopredictoutcomewithserotninreiuptakeinkibitorsandplacebointhetreatmentofobsessive-compulsivedisorderJ.Am-J-Psychiatry,1999,156(9):140916.(:)(:2003-07-09)0752720038HEILONGJIANGMEDICALJOURNALVol.27,No.8Aug.2003